Shea Levin — text status

The Trump administration is considering rules allowing most U.S. pharmaceutical deals with Chinese drug developers to continue, while restricting transactions involving pathogens or biotechnology with potential military uses, Reuters reports. Drugmakers including Pfizer have opposed broader restrictions, warning they could limit access to new medicines from China. The rules are still being discussed and are not expected before Trump meets Xi next week.